To support patients through the Epioxa cross-linking treatment journey, Glaukos has launched EpioxaCareConnect. The comprehensive source provides support with benefit investigations, prior authorization and appeals, and financial assistance resources. Each patient enrolled in EpioxaCareConnect is also paired with a patient access liaison (PAL) who can guide them through the process to accessing treatment, the company said in a press release. EpioxaCareConnect consists of the following components:

• Access and Reimbursement. EpioxaCareConnect can perform a benefits investigation, provide prior authorization requirements and estimated patient out-of-pocket (OOP) costs, and determine financial assistance eligibility. It can also offer support through prior authorizations/predeterminations and peer-to-peer reviews.

• Specialty Pharmacy Support. Practices can send Epioxa specialty pharmacy prescriptions directly to EpioxaCareConnect. If the payer allows Epioxa access through specialty pharmacy, EpioxaCareConnect will work directly with the specialty pharmacy to get the prescription filled and administer patient financial assistance.

• Patient Support Through Glaukos’ PAL Team. Upon enrollment, each patient is paired with a dedicated PAL who offers one-on-one, nonmedical support. The PAL answers logistical questions, guides patients through insurance and access processes, and helps ensure a smooth start to treatment. PALs stay engaged after first-eye treatment to support recovery and coordinate second-eye treatment, if needed.

• Financial Support. Through the Epioxa Copay Program, commercially insured patients may be eligible to pay as little as $0 out of pocket toward the cost of Epioxa and the cross-linking procedure. Glaukos also offers a patient assistance program for eligible US residents who are uninsured or underinsured.

• Additional Resources Available on www.Epioxa.com. Resources available to practices include the EpioxaCareConnect patient enrollment form; billing and coding tools like billing guides, template letters, and payer policy information to support access and appropriate reimbursement; and patient-friendly education materials on coverage, insurance processes, and financial assistance options.

On October 20, 2025, Glaukos announced that the US Food and Drug Administration (FDA) approved Epioxa HD/Epioxa, the first epithelium-on, oxygen-enriched corneal cross-linking treatment for keratoconus. Epioxa uses new proprietary bioactivated topical formulations which are catalyzed by oxygen and a UV light source. It has been proven to treat keratoconus by slowing or halting the disease process to help preserve vision, and is designed for improved patient comfort with rapid recovery. Most ocular and nonocular treatment-related adverse events were mild and transient in the 2 phase 3 pivotal trials. Some initial Epioxa procedures are anticipated to begin in April, the company said in the press release.